Valuation: Incyte Corporation

Market Cap 2.35TCr 12TCr 2.09TCr 1.93TCr 1.75TCr 3.28TCr 2,22600Cr 3.33TCr 23TCr 9.22TCr 1,16700Cr 8.8TCr 8.61TCr 3,67800Cr P/E 2026 *
64.5x
P/E 2027 * 16.3x
Enterprise Value 1.92TCr 9.66TCr 1.71TCr 1.58TCr 1.43TCr 2.68TCr 1,82100Cr 2.73TCr 19TCr 7.54TCr 95TCr 7.2TCr 7.05TCr 3,00800Cr EV / Sales 2026 *
3.23x
EV / Sales 2027 * 2.81x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day+2.54%
1 week+2.54%
Current month-11.49%
1 month-11.49%
3 months-2.28%
6 months+22.07%
Current year+4.03%
1 week 288.27
Extreme 288.27
288.55
1 month 280
Extreme 280
310.93
Current year 232.56
Extreme 232.56
328.68
1 year 232.56
Extreme 232.56
328.68
3 years 135.9
Extreme 135.9
328.68
5 years 135.9
Extreme 135.9
328.68
10 years 135.9
Extreme 135.9
328.68
Manager TitleAgeSince
Chief Executive Officer 58 26/06/2025
Director of Finance/CFO 57 04/05/2026
President 62 05/06/2023
Director TitleAgeSince
Chairman 59 26/06/2025
Director/Board Member 72 20/01/2015
Director/Board Member 64 20/01/2015
Change 5-day change 1-year change 3-year change Capi.($)
+2.54%+2.54% - - 2.35TCr
-2.54%+1.31%+54.27%+117.14% 1,13500Cr
-1.42%+3.23%+38.56%+74.05% 64TCr
+0.16%+0.08%+25.29%+96.64% 50TCr
-0.31%+3.09%+44.14%+64.55% 38TCr
-1.34%-0.47%+66.04%+40.18% 36TCr
-0.68%+2.65%+22.98%+49.15% 29TCr
-1.20%+3.04%+2.33%+21.60% 27TCr
-1.79%+1.57%+50.56%+61.40% 24TCr
-0.73%-0.10%+29.02%+99.06% 19TCr
Average -0.73%+1.60%+37.02%+69.31% 44.49TCr
Weighted average by Cap. -1.32%+1.63%+41.02%+80.33%

Financials

2026 *2027 *
Net sales 593.68Cr 2.99TCr 530.15Cr 489.76Cr 443.83Cr 830.35Cr 56TCr 844.09Cr 5.89TCr 2.33TCr 30TCr 2.23TCr 2.18TCr 93TCr 624.07Cr 3.14TCr 557.29Cr 514.83Cr 466.55Cr 872.86Cr 59TCr 887.3Cr 6.2TCr 2.45TCr 31TCr 2.34TCr 2.29TCr 98TCr
Net income 38Cr 189.81Cr 34Cr 31Cr 28Cr 53Cr 3.58TCr 54Cr 374.05Cr 148.09Cr 1.87TCr 141.41Cr 138.4Cr 5.91TCr 148.28Cr 746.95Cr 132.41Cr 122.32Cr 110.85Cr 207.39Cr 14TCr 210.82Cr 1.47TCr 582.78Cr 7.37TCr 556.47Cr 544.64Cr 23TCr
Net Debt -426.87Cr -2.15TCr -381.2Cr -352.15Cr -319.13Cr -597.05Cr -41TCr -606.93Cr -4.24TCr -1.68TCr -21TCr -1.6TCr -1.57TCr -67TCr -594.61Cr -3TCr -530.99Cr -490.53Cr -444.53Cr -831.66Cr -56TCr -845.42Cr -5.9TCr -2.34TCr -30TCr -2.23TCr -2.18TCr -93TCr
Projected Income Statement - Annual - Incyte Corporation
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Incyte Corporation
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
115.71USD
Average target price
129.54USD
Spread / Average Target
+11.95%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Incyte Corporation